共 27 条
- [2] COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY [J]. ANNALS OF STATISTICS, 1982, 10 (04) : 1100 - 1120
- [3] Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study (Apr 30, 10.1016/S1473-3099(24)00215-9, 2024) [J]. LANCET INFECTIOUS DISEASES, 2024, 24 (07) : e419 - e419
- [4] Quantifying possible bias in clinical and epidemiological studies with quantitative bias analysis: common approaches and limitations [J]. BMJ-BRITISH MEDICAL JOURNAL, 2024, 385
- [6] Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, 2023, Recomendaciones de utilizacion de nirsevimab frente a virus respiratorio sincitial para la temporada 2023-2024. Recommendations for use of nirsevimab against respiratory syncytial virus for the 2023-2024 season
- [7] COX DR, 1972, J R STAT SOC B, V34, P187
- [8] Direccion General de Salud Publica de la Comunidad de Madrid, 2023, Documento tecnico de Inmunizacion frente al Virus Respiratorio Sincitial (VRS) en lactantes en la Comunidad de Madrid en la temporada 2023-2024. Technical document on Immunisation against Respiratory Syncytial Virus (RSV) in infants in the Madrid region in the 2023-2024 season
- [9] Direccion General de Salud Publica de la Comunidad de Madrid. Situacion epidemiologica del Virus Respiratorio Sincitial (VRS). Comunidad de Madrid. Temporadas, 2016, Epidemiological situation of Respiratory Syncytial Virus (RSV). Madrid region. Seasons 2016/17 to 2022/23.